RetinaLyze International

Hjem
Danmark
Skovlunde
RetinaLyze International

Safe, fast and efficient retinal investigations with RetinaLyze AI and Telemedicine.

03/06/2026

See you at the 53rd Congress of the Canary Islands Society of Ophthalmology!

From June 4–6, RetinaLyze will be represented by Bloss Group in Maspalomas, Gran Canaria.

During the congress, you will have the opportunity to learn more about RetinaLyze, our AI-based software for automated retinal image analysis and support for ophthalmic screening.

The event will bring together innovation, diagnostics, and new technologies applied to clinical ophthalmology and we are excited to be part of it through our trusted partner, Bloss Group.

📍 Hotel Maspalomas Tabaiba Princess · Gran Canaria
📅 June 4–6, 2026

We look forward to seeing you there! 🙌

01/06/2026

Glaucoma screening is rarely based on one measure alone.

RetinaLyze Glaucoma analyses colour fundus images to assess haemoglobin levels in the optic nerve head. The result can help indicate whether colour variations are present that may be associated with early signs of glaucoma.

It is a practical screening layer, not a diagnosis.

A yellow result becomes more clinically relevant when combined with other risk factors: family history, elevated IOP, asymmetry between eyes, OCT findings, or visual field defects.

This is where AI-supported screening can be useful in practice.

It gives structure to the assessment, but the decision still depends on the broader clinical picture and, when needed, referral to an ophthalmologist.

27/05/2026

A 15-year follow-up from the Blue Mountains Eye Study gives a useful reminder of why glaucoma risk assessment cannot rely on one measurement alone.

In this older Australian cohort, the age-standardized 15-year incidence of definite and probable open-angle glaucoma was 5.67%. The strongest risk factors were age, pseudoexfoliation, myopia of 3 diopters or more, and intraocular pressure.

IOP mattered, clearly. Each 1 mmHg increase was associated with a 24% higher risk of developing open-angle glaucoma. But the study also found that only 13.6% of participants who developed glaucoma had ocular hypertension at baseline.

That is clinically important.

It reinforces what many clinicians see in practice: glaucoma risk is often visible in the pattern, not just the pressure. Optic nerve appearance, structural change, refractive status, pseudoexfoliation, and longitudinal follow-up all matter.

For optometrists and ophthalmologists, studies like this support a more layered approach to glaucoma detection. Not every patient at risk will present with high IOP. And not every suspicious finding will become glaucoma. The value is in combining data over time and knowing which patients deserve closer attention.

Early recognition is still one of the most practical ways to protect vision.

Read the full study here: https://linkinghub.elsevier.com/retrieve/pii/S0161642z026000151

25/05/2026

AI-supported AMD screening can help detect signs of dry AMD, but it does not remove the need to listen carefully to the patient.

RetinaLyze AMD screens fundus images for drusen and other minor white lesions that may indicate early signs of dry age-related macular degeneration. The result gives a colour-coded summary and an overlay showing detected changes.

But wet AMD is different.

Visual acuity, symptoms, and tools such as the Amsler grid still matter. A patient describing wavy lines, central blur, or blind spots should not be reassured by image analysis alone.

That is an important clinical point.

Good screening is not just about detecting what is visible in an image. It is about combining the image, the patient’s symptoms, and the professional’s judgement into the next right step.

20/05/2026

RetinaLyze will be represented by Topcon Healthcare at the 17th EGS Congress in Brussels, taking place from May 30 to June 2, 2026.

At the Topcon booth, visitors will be able to see how Harmony connects with devices and leading AI technologies to support more efficient, connected clinical workflows.

For glaucoma care, that connection matters.

Glaucoma progression is rarely about a single image or a single measurement. It is about following change over time, bringing information together, and giving clinicians a clearer view of what may be happening between visits.

With RetinaLyze Advanced Glaucoma progression capabilities, RetinaLyze supports a more structured way to assess longitudinal changes and help clinicians recognize progression earlier and more consistently.

We are pleased to be part of the conversation at EGS 2026 through Topcon, alongside technologies that help make eye care workflows more connected, practical, and clinically useful.

18/05/2026

Diabetic retinopathy screening is not only about finding advanced disease.

Often, the important step is recognising early signs and making sure the right patient gets the right follow-up.

RetinaLyze DR analyses fundus images for typical signs associated with diabetic retinopathy, such as microaneurysms and minor haemorrhages. Results are shown with a simple colour summary and an overlay that marks detected changes.

For clinical communication, the nuance matters.

A yellow result may reflect early changes, but it can also be influenced by temporary haemorrhages or image artefacts. A repeated yellow result, symptoms, or known diabetes changes how the result should be handled.

This is where screening becomes more than a result on a screen.

It becomes a structured conversation about risk, follow-up, and when to involve an ophthalmologist.

13/05/2026

A retinal screening is only as useful as the image behind it.

Whether an assessment is manual or AI-supported, image quality remains one of the most important parts of the workflow. Reflections, shadows, dust on the lens, or artefacts around the macula and optic nerve head can all affect interpretation.

One practical habit is to look at where a suspicious spot appears.

If it stays in the same position in the image, it may be an artefact.
If it stays in the same position relative to the macula or optic nerve head, it is more likely to represent a retinal change.

This is a small detail, but it matters in daily practice.

AI can support screening, but the fundamentals still count: good capture technique, clinical awareness, and knowing when to retake an image or ask for specialist backup.

11/05/2026

𝗡𝗲𝘄 𝗱𝗲𝘃𝗶𝗰𝗲 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻: 𝗠𝗲𝗱𝗶𝗪𝗼𝗿𝗸𝘀 𝗙𝗖𝟭𝟲𝟮

We’re pleased to share that RetinaLyze now integrates with the MediWorks FC162 automatic fundus camera.

That means you can capture fundus images with the FC162, analyze them with RetinaLyze, and get instant, AI-powered insights for signs of eye diseases without adding unnecessary steps to the clinical workflow.

The FC162 is designed for efficient retinal screening, with automatic alignment, autofocus and voice-guided capture. It also supports wide-field imaging, mobile screening scenarios and easy image transfer from camera to PC.

Why this matters for clinics & screening providers:

Smooth workflow: Move images from the FC162 into RetinaLyze for automated analysis and reporting.
Practical screening setup: A portable fundus camera paired with AI analysis can support community screening, follow-up management and examination center workflows.
Faster decisions: Help clinicians identify signs of retinal disease earlier and route patients for further assessment when needed.
Consistency across sites: Objective, reproducible outputs across locations, operators and time.

If you use the MediWorks FC162 today and want to enable RetinaLyze, book a quick demo and we’ll get you set up.

👉 Demo / trial: https://www.retinalyze.com/try

This announcement refers only to device compatibility and workflow integration. It does not imply a commercial partnership, distribution agreement, or regional representation between RetinaLyze and MediWorks.

06/05/2026

AI in eye care is most useful when it fits into the clinical workflow, not when it tries to replace it.

RetinaLyze is designed to support screening and triage by analysing fundus images and OCT scans for signs that may need further attention. The result is not a diagnosis. It is a structured way to help eye care professionals identify which patients may need closer evaluation, follow-up, or referral.

That distinction matters.

For optometrists and clinical teams, the value is often in the practical details:
good image quality, clear colour-coded results, overlays that make findings easier to review, and the option to escalate uncertain cases through telemedicine.

The goal is not to remove clinical judgement.

It is to make screening more consistent, scalable, and easier to integrate into everyday practice.

04/05/2026

Bloss Group will be representing RetinaLyze at SECOIR & SECOMIR 2026 in A Coruña.

From 6-9 May, you can visit them at stand nº45 in PALEXCO, where they will be presenting a strong selection of technologies for ophthalmology, diagnostics, surgery, and clinical workflow.

We are pleased that RetinaLyze will be part of this lineup, showing how AI-supported eye screening can help make retinal assessment more accessible and integrated into everyday eye care.

Events like SECOIR & SECOMIR are a good opportunity to see how different technologies connect across the patient journey from diagnosis and screening to treatment planning and surgery.

A big thank you to Bloss Group for representing us.

📍 Stand nº45
📅 6–9 May 2026
📍 A Coruña · PALEXCO

Adresse

Lyskær 1
Skovlunde
2730

Hvad er åbningstiderne?

Mandag	09:00 - 17:30
Tirsdag	09:00 - 17:30
Onsdag	09:00 - 17:30
Torsdag	09:00 - 17:30
Fredag	09:00 - 17:30

Internet side

https://retinalyze.com/

Underretninger

Vær den første til at vide, og lad os sende dig en email, når RetinaLyze International sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Virksomheden

Send en besked til RetinaLyze International:

Genveje

Vil du plassere din virksomhed på toppen av Ingeniørvirksomhed-listen i Skovlunde?